-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

Benzinga·10/12/2026 13:27:50
Listen to the news
Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.